179 related articles for article (PubMed ID: 35020754)
1. SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.
Khateeb D; Gabrieli T; Sofer B; Hattar A; Cordela S; Chaouat A; Spivak I; Lejbkowicz I; Almog R; Mandelboim M; Bar-On Y
PLoS Pathog; 2022 Jan; 18(1):e1010242. PubMed ID: 35020754
[TBL] [Abstract][Full Text] [Related]
2. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
3. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
[TBL] [Abstract][Full Text] [Related]
4. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
5. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
Lee E; Sandgren K; Duette G; Stylianou VV; Khanna R; Eden JS; Blyth E; Gottlieb D; Cunningham AL; Palmer S
J Virol; 2021 Feb; 95(6):. PubMed ID: 33443088
[TBL] [Abstract][Full Text] [Related]
6. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 evolution during treatment of chronic infection.
Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.
Trimpert J; Herwig S; Stein J; Vladimirova D; Adler JM; Abdelgawad A; Firsching TC; Thoma T; Sehouli J; Osterrieder K; Gruber AD; Sawitzki B; Sander LE; Cichon G
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835096
[TBL] [Abstract][Full Text] [Related]
9. Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection.
Perkmann T; Perkmann-Nagele N; Koller T; Mucher P; Radakovics A; Wolzt M; Wagner OF; Binder CJ; Haslacher H
Eur J Clin Invest; 2021 Nov; 51(11):e13632. PubMed ID: 34337738
[TBL] [Abstract][Full Text] [Related]
10. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
11. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
Bates TA; Leier HC; Lyski ZL; McBride SK; Coulter FJ; Weinstein JB; Goodman JR; Lu Z; Siegel SAR; Sullivan P; Strnad M; Brunton AE; Lee DX; Adey AC; Bimber BN; O'Roak BJ; Curlin ME; Messer WB; Tafesse FG
Nat Commun; 2021 Aug; 12(1):5135. PubMed ID: 34446720
[TBL] [Abstract][Full Text] [Related]
13. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
14. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
Kawasuji H; Morinaga Y; Tani H; Saga Y; Kaneda M; Murai Y; Ueno A; Miyajima Y; Fukui Y; Nagaoka K; Ono C; Matsuura Y; Niimi H; Yamamoto Y
Microbiol Spectr; 2021 Dec; 9(3):e0056121. PubMed ID: 34851162
[TBL] [Abstract][Full Text] [Related]
15. An Integrated Platform for Serological Detection and Vaccination of COVID-19.
Wei SC; Hsu WT; Chiu CH; Chang FY; Lo HR; Liao CY; Yang HI; Chou YC; Tsai CH; Chao YC
Front Immunol; 2021; 12():771011. PubMed ID: 35003088
[TBL] [Abstract][Full Text] [Related]
16. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.
Reynolds CJ; Gibbons JM; Pade C; Lin KM; Sandoval DM; Pieper F; Butler DK; Liu S; Otter AD; Joy G; Menacho K; Fontana M; Smit A; Kele B; Cutino-Moguel T; Maini MK; Noursadeghi M; ; Brooks T; Semper A; Manisty C; Treibel TA; Moon JC; ; McKnight Á; Altmann DM; Boyton RJ
Science; 2022 Jan; 375(6577):183-192. PubMed ID: 34855510
[TBL] [Abstract][Full Text] [Related]
17. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
[TBL] [Abstract][Full Text] [Related]
18. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
19. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Lucas C; Vogels CBF; Yildirim I; Rothman JE; Lu P; Monteiro V; Gehlhausen JR; Campbell M; Silva J; Tabachnikova A; Peña-Hernandez MA; Muenker MC; Breban MI; Fauver JR; Mohanty S; Huang J; ; Shaw AC; Ko AI; Omer SB; Grubaugh ND; Iwasaki A
Nature; 2021 Dec; 600(7889):523-529. PubMed ID: 34634791
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Serological Characterization of the SARS-CoV-2 Delta Variant in Bangladesh in 2021.
Ghosh AK; Kaiser M; Molla MMA; Nafisa T; Yeasmin M; Ratul RH; Sharif MM; Akram A; Hosen N; Mamunur R; Amin MR; Islam A; Hoque ME; Landt O; Lytton SD
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
